Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001968582-23-000263
Filing Date
2023-06-20
Accepted
2023-06-20 16:52:55
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 2902
  Complete submission text file 0001968582-23-000263.txt   4313
Mailing Address C/O AVEXIS, INC. 2275 HALF DAY ROAD, SUITE 200 BANNOCKBURN IL 60015
Business Address
Session R.A. II (Reporting) CIK: 0001701846 (see all company filings)

Type: 144

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39536 | Film No.: 231025958
SIC: 2836 Biological Products, (No Diagnostic Substances)